Abbott to commercialize Celeras CE-marked KIF6 genotyping assay outside U.

‘We’re delighted that Abbott will commercialize our CE-marked KIF6 check outside the U.S. ‘We believe the mix of Abbott’s marketing reach, expertise in coronary disease and the widespread placement of the m2000 presents a good opportunity for this test to impact the customized treatment of cardiovascular disease.’ ‘Celera’s KIF6 test represents the first cardiovascular assay on the m2000 program, and will offer an innovative, new check for physicians in assisting them identify patients at risk of cardiovascular system disease,’ said Stafford O’Kelly, head of Abbott’s molecular diagnostics business.Wedin, M.D., Ph.D., Ian J. Neeland, M.D., Ivan S. Yuhanna, Ph.D., Daniel R. Rader, M.D., James A. De Lemos, M.D., and Philip W. Shaul, M.D.: HDL Cholesterol Efflux Capability and Incident Cardiovascular Occasions A low level of high-density lipoprotein cholesterol is a significant independent risk element for atherosclerotic cardiovascular disease.1 However, in randomized, controlled trials, high-dose niacin or inhibitors of cholesteryl ester transfer protein did not improve cardiovascular outcomes despite significantly increasing the HDL cholesterol level.2-5 Furthermore, genetic variants associated with HDL cholesterol levels aren’t associated with cardiovascular disease often.